Framing: assign obligations by activity and product before buying traceability software. FDA’s current small-dispenser exemption is limited to specified requirements. Its eligibility definition concerns the owning company’s pharmacist and qualified pharmacy-technician employees; the letter preserves other obligations. A clinic’s prescriber count is therefore not the relevant eligibility test. (fda.gov)
Put to: Jesse Dresser and Michael Ganio.
Buyer owner: Compliance lead and procurement.
Why it matters: The buyer needs to know what it must do itself, what its trading partners must do and what records must remain accessible during a recall or suspect-product investigation.
A good answer should cover:
- Whether the clinic’s actual activities make it a relevant trading partner or dispenser.
- The applicable obligations for the product and transaction, including any exclusions or exemptions.
- Supplier authorisation checks, required transaction records and suspect-product escalation.
- How records remain usable if a software vendor, wholesaler or pharmacy relationship ends.
- The precise basis and dates for any claimed exemption.
Follow-up that tests the answer: “Produce the records and escalation chain for one selected package or lot without relying on the account manager.”
Evidence to request: A counsel-approved responsibility matrix and traceability drill. Keep provenance controls for compounded preparations distinct from an unsupported assumption that every product follows the same DSCSA pathway.
Expert quote — reserved: ________________________________________
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act